---
schema_version: "secwatch.filing_event.v1"
accession: "0001656423-22-000039"
form_type: "8-K"
ticker: "BXP"
cik: "0001037540"
company_name: "BXP, Inc."
filed_at: "2022-10-26T23:59:59+00:00"
generated_at: "2026-06-23T00:39:54.902961+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BXP Q3 EPS $2.29 beats mid-point by $1.54; FFO $1.91; 2023 guidance lower

## Summary
- Revenue $790.5M (+8.3% YoY); net income $361M ($2.29 EPS); FFO $299.8M ($1.91).
- EPS beat included $1.50 gain on sale of 601 Mass Ave ($531M gross); FFO beat by $0.04.
- FY2022 EPS guidance $5.55-$5.57, FFO $7.51-$7.53; FY2023 EPS $2.27-$2.42, FFO $7.15-$7.30.
- Leased 1.4M SF in Q3; acquired 125 Broadway lab in Kendall Sq for ~$592.4M; disposed 601 Mass Ave and land parcels.
- Agreed to acquire ~27% interest in 200 Fifth Ave, NYC for ~$280.2M and sell Avant residential for ~$141M.

## SEC filing metadata
- accession: 0001656423-22-000039
- form_type: 8-K
- ticker: BXP
- cik: 0001037540
- company_name: BXP, Inc.
- filed_at: 2022-10-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1037540/000165642322000039/0001656423-22-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1037540/000165642322000039/bxp-20221025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001656423-22-000039
- JSON: https://secwatch.observer/filing/0001656423-22-000039.json
- Plain text: https://secwatch.observer/filing/0001656423-22-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.